We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+6.28%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$511M
AUM Growth
–
Cap. Flow
+$509M
Cap. Flow %
99.56%
Top 10 Hldgs %
53.04%
Holding
51
New
51
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
NTUS
Natus Medical Inc
NTUS
+$35.3M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$33.6M
3
ASRT
Assertio
ASRT
+$31.3M
4
ANGO icon
AngioDynamics
ANGO
+$29M
5
NVDQ
Novadaq Technologies Inc.
NVDQ
+$25.4M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 73.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTUS
1
DELISTED
Natus Medical Inc
NTUS
$35.4M 6.92%
+2,590,992
New +$35.3M
TEVA icon
2
Teva Pharmaceuticals
TEVA
$36.5B
$33.8M 6.62%
+863,236
New +$33.6M
ASRT
3
DELISTED
Assertio
ASRT
$31.6M 6.18%
+93,700
New +$31.3M
ANGO icon
4
AngioDynamics
ANGO
$564M
$30.8M 6.02%
+2,726,651
New +$29M
IPXL
5
DELISTED
Impax Laboratories, Inc.
IPXL
$27.9M 5.45%
+1,398,543
New +$24.8M
NVDQ
6
DELISTED
Novadaq Technologies Inc.
NVDQ
$26.7M 5.21%
+1,983,442
New +$25.4M
NPSP
7
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$25.6M 5.02%
+1,696,754
New +$23.5M
LCI
8
DELISTED
Lannett Company, Inc.
LCI
$21.7M 4.25%
+455,565
New +$20.6M
AVDL
9
DELISTED
Avadel Pharmaceuticals
AVDL
$19.3M 3.77%
+3,139,131
New +$16.2M
IART icon
10
Integra LifeSciences
IART
$1.49B
$18.4M 3.6%
+1,230,365
New +$18M
ALKS icon
11
Alkermes
ALKS
$8.7B
$17.2M 3.37%
+600,000
New +$17.5M
PGNX
12
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$15.6M 3.05%
+3,500,615
New +$15.7M
EBS icon
13
Emergent Biosolutions
EBS
$391M
$15.5M 3.03%
+1,074,248
New +$15.6M
AUXL
14
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$13.3M 2.6%
+800,000
New +$12.8M
CEMP
15
DELISTED
Cempra, Inc.
CEMP
$12.1M 2.36%
+1,555,147
New +$10.7M
DSCI
16
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$10.3M 2.02%
+775,000
New +$9.96M
RIGL icon
17
Rigel Pharmaceuticals
RIGL
$750M
$10.2M 1.99%
+305,000
New +$13.8M
TTPH
18
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$10M 1.96%
+71,416
New +$11.3M
ANAC
19
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$9.64M 1.89%
+1,724,028
New +$10.4M
ARTC
20
DELISTED
ARTHROCARE CORP
ARTC
$9.17M 1.79%
+265,585
New +$9.13M
HITK
21
DELISTED
HI-TECH PHARMACAL INC
HITK
$9.07M 1.77%
+273,232
New +$9.09M
SLTM
22
DELISTED
SOLTA MED INC (DE)
SLTM
$8.96M 1.75%
+3,928,135
New +$8.28M
BDSI
23
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$8.62M 1.69%
+2,122,054
New +$9.96M
ATRC icon
24
AtriCure
ATRC
$1.78B
$7.52M 1.47%
+791,841
New +$6.9M
OFIX icon
25
Orthofix Medical
OFIX
$470M
$6.72M 1.32%
+250,000
New +$7.49M
1
2 3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for Broadfin Capital, which disclosed 51 positions worth $511M. Its ten largest holdings account for 53% of the portfolio.

Its largest position is Natus Medical Inc: 2,590,992 shares worth $35.4M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets.

  • Broadfin Capital's largest Q2 2013 buy was Natus Medical Inc: 2,590,992 shares worth $35.4M.
  • Broadfin Capital's ten largest holdings make up 53% of its $511M portfolio in Q2 2013.
  • Broadfin Capital disclosed 51 positions in Q2 2013, its first 13F filing on record.

Based on Broadfin Capital's 13F filing for Q2 2013, filed 14 Aug 2013.